ONGOING STUDY:

An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma.

 

DESIGN

Phase II, open-label and single-center study.

The patient population that will be evaluated in this study have advanced/metastatic disease and will have received one (or possibly multiple) lines of treatment for advanced/metastatic disease.

 

OBJECTIVES

Primary objectives:

           To determine the safety of LTX-315 as part of adoptive T-cell therapy in advanced/metastatic soft tissue sarcoma
           To determine the ability of LTX-315 to induce T-cell infiltration prior to TIL expansion.

Secondary objectives:

           To assess the ability to expand CD8+ T-cells from tumour tissues
           To assess the anti-tumour effect of LTX-315 as part of adoptive T-cell therapy in advanced/metastatic soft tissue sarcoma

 

PLANNED STUDY:

The Company plans to initiate phase II trial with LTX-315, multi arm “pick the winner” design in different combinations